Last reviewed · How we verify
NCT06298123
Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling
trial testing Anti-PD-1 monoclonal antibody in Hepatocellular Carcinoma in 304 participants. Completed in 1 February 2023.
1 February 2023
Quick facts
| Lead sponsor | Chen Xiaoping |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 304 |
| Start date | 1 February 2019 |
| Primary completion | 1 February 2023 |
| Estimated completion | 1 February 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Anti-PD-1 monoclonal antibody — full drug profile →
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
- Adjuvant Immunotherapy — all drugs for Adjuvant Immunotherapy →
- Checkpoint Inhibitor — all drugs for Checkpoint Inhibitor →
Sponsor
Chen Xiaoping — full company profile →
Who can join
Adults 18 to 75, any sex, with Hepatocellular Carcinoma or Adjuvant Immunotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study was to analyse the independent risk factors for hepatocellular carcinoma (HCC) patients undergoing adjuvant immunotherapy after liver resection surgery, and to develop a prognostic model based on these factors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06298123
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anti-PD-1 monoclonal antibody
Trials testing the same drug.
- NCT07365592 — Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC · Phase 1, PHASE2 · not yet recruiting
- NCT06603844 — First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. · Phase 1, PHASE2 · recruiting
- NCT06556199 — A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primar · Phase 1, PHASE2 · recruiting
- NCT06728657 — Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma · Phase 2 · suspended
- NCT06349044 — A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed · NA · recruiting
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other Chen Xiaoping trials
Trials by the same sponsor.
- NCT06463444 — Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models · Phase 1 · recruiting
- NCT06420440 — Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model · Phase 2 · recruiting
- NCT06311916 — Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. · Phase 4 · not yet recruiting
- NCT06311942 — Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. · Phase 4 · recruiting
- NCT06311929 — Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06298123 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chen Xiaoping
- Last refreshed: 7 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06298123.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing